SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001144204-18-050743
Filing Date
2018-09-25
Accepted
2018-09-25 17:13:54
Documents
7
Period of Report
2018-09-20
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 5.03: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K tv503422_8k.htm 8-K 23097
2 EXHIBIT 1.1 tv503422_ex1-1.htm EX-1.1 297109
3 EXHIBIT 3.1 tv503422_ex3-1.htm EX-3.1 100667
4 EXHIBIT 4.1 tv503422_ex4-1.htm EX-4.1 215200
5 EXHIBIT 4.2 tv503422_ex4-2.htm EX-4.2 84853
6 EXHIBIT 99.1 tv503422_ex99-1.htm EX-99.1 10180
7 GRAPHIC tv503422_ex99-1img1.jpg GRAPHIC 5412
  Complete submission text file 0001144204-18-050743.txt   740005
Mailing Address 400 OYSTER POINT BLVD SUITE 505 SAN FRANCISCO CA 94080
Business Address 400 OYSTER POINT BLVD SUITE 505 SAN FRANCISCO CA 94080 6502444990
TITAN PHARMACEUTICALS INC (Filer) CIK: 0000910267 (see all company filings)

IRS No.: 943171940 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-13341 | Film No.: 181086289
SIC: 2836 Biological Products, (No Diagnostic Substances)
Assistant Director 1